CTBO — Cantabio Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Annual income statement for Cantabio Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2014 March 31st | R2015 March 31st | 2016 March 31st | 2017 March 31st | 2018 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.087 | 0.03 | 0.733 | 1.07 | 1.59 |
| Operating Profit | -0.087 | -0.03 | -0.733 | -1.07 | -1.59 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.087 | 0.078 | -0.751 | -1.11 | -2.01 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.087 | 0.078 | -0.751 | -1.11 | -2.01 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.087 | 0.078 | -0.751 | -1.11 | -2.01 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.087 | 0.078 | -0.751 | -1.11 | -2.01 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -19 | 26.4 | -236 | -207 | -286 |
| Dividends per Share |